These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17482438)

  • 1. Bioreductive drugs: from concept to clinic.
    McKeown SR; Cowen RL; Williams KJ
    Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):427-42. PubMed ID: 17482438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxic sensitizer and cytotoxin for head and neck cancer.
    Lee DJ; Moini M; Giuliano J; Westra WH
    Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia.
    Denny WA; Wilson WR
    Expert Opin Investig Drugs; 2000 Dec; 9(12):2889-901. PubMed ID: 11093359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia: targeting the tumour.
    Boyle RG; Travers S
    Anticancer Agents Med Chem; 2006 Jul; 6(4):281-6. PubMed ID: 16842231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
    Hicks KO; Siim BG; Jaiswal JK; Pruijn FB; Fraser AM; Patel R; Hogg A; Liyanage HD; Dorie MJ; Brown JM; Denny WA; Hay MP; Wilson WR
    Clin Cancer Res; 2010 Oct; 16(20):4946-57. PubMed ID: 20732963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation.
    McKeown SR; Friery OP; McIntyre IA; Hejmadi MV; Patterson LH; Hirst DG
    Br J Cancer Suppl; 1996 Jul; 27():S39-42. PubMed ID: 8763843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tirapazamine: from bench to clinical trials.
    Marcu L; Olver I
    Curr Clin Pharmacol; 2006 Jan; 1(1):71-9. PubMed ID: 18666379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine.
    Friery OP; Gallagher R; Murray MM; Hughes CM; Galligan ES; McIntyre IA; Patterson LH; Hirst DG; McKeown SR
    Br J Cancer; 2000 Apr; 82(8):1469-73. PubMed ID: 10780528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation.
    Keohane A; Godden J; Stratford IJ; Adams GE
    Br J Cancer; 1990 May; 61(5):722-6. PubMed ID: 2110815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
    Papadopoulou MV; Ji M; Rao MK; Bloomer WD
    Oncol Res; 2001; 12(8):325-33. PubMed ID: 11589303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors.
    Shulman LN; Buswell L; Riese N; Doherty N; Loeffler JS; von Roemeling RW; Coleman CN
    Int J Radiat Oncol Biol Phys; 1999 May; 44(2):349-53. PubMed ID: 10760430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel radiation sensitizers targeting tissue hypoxia.
    Rowinsky EK
    Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):61-70. PubMed ID: 10550828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The experimental development of bioreductive drugs and their role in cancer therapy.
    Workman P; Stratford IJ
    Cancer Metastasis Rev; 1993 Jun; 12(2):73-82. PubMed ID: 8375022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
    Guise CP; Mowday AM; Ashoorzadeh A; Yuan R; Lin WH; Wu DH; Smaill JB; Patterson AV; Ding K
    Chin J Cancer; 2014 Feb; 33(2):80-6. PubMed ID: 23845143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies.
    Brown JM
    Mol Med Today; 2000 Apr; 6(4):157-62. PubMed ID: 10740254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice.
    Lee AE; Wilson WR
    Toxicol Appl Pharmacol; 2000 Feb; 163(1):50-9. PubMed ID: 10662604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo: comparison with tirapazamine.
    Papadopoulou MV; Ji M; Bloomer WD
    Oncol Res; 2002; 13(1):47-54. PubMed ID: 12201674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of low pH and hypoxia on the cytotoxic effects of SR4233 and mitomycin C in vitro.
    Skarsgard LD; Vinczan A; Skwarchuk MW; Chaplin DJ
    Int J Radiat Oncol Biol Phys; 1994 May; 29(2):363-7. PubMed ID: 8195034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N.
    Gallagher R; Hughes CM; Murray MM; Friery OP; Patterson LH; Hirst DG; McKeown SR
    Br J Cancer; 2001 Aug; 85(4):625-9. PubMed ID: 11506506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia.
    Siim BG; Menke DR; Dorie MJ; Brown JM
    Cancer Res; 1997 Jul; 57(14):2922-8. PubMed ID: 9230202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.